Relapsing-remitting multiple sclerosis
Not recruitingStudy on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
- Disease:Relapsing-remitting multiple sclerosis
- Substances:DIMENHYDRINATEFingolimod+2
Belgium- Participants:0–17 years
- Substances:DIMENHYDRINATE
- Sponsor:F. Hoffmann-La Roche AG














